↓ Skip to main content

Cochrane Database of Systematic Reviews

New generation antipsychotics for first episode schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, October 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

policy
1 policy source
twitter
8 tweeters
weibo
1 weibo user
facebook
1 Facebook page

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
128 Mendeley
Title
New generation antipsychotics for first episode schizophrenia
Published in
Cochrane database of systematic reviews, October 2003
DOI 10.1002/14651858.cd004410
Pubmed ID
Authors

Johannes Hamann, Werner Kissling, Stefan Leucht, Christine Rummel-Kluge

Abstract

The new generation antipsychotics are associated with a lower risk of adverse effects compared with drugs such as haloperidol. Many treatment guidelines recommend the use of new generation ('atypical') antipsychotic drugs for people with a first episode of schizophrenia.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 <1%
United States 1 <1%
Canada 1 <1%
Unknown 125 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 16%
Researcher 18 14%
Student > Ph. D. Student 14 11%
Student > Bachelor 12 9%
Student > Doctoral Student 11 9%
Other 36 28%
Unknown 16 13%
Readers by discipline Count As %
Medicine and Dentistry 45 35%
Psychology 27 21%
Nursing and Health Professions 9 7%
Pharmacology, Toxicology and Pharmaceutical Science 7 5%
Social Sciences 4 3%
Other 8 6%
Unknown 28 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2017.
All research outputs
#2,918,244
of 17,360,236 outputs
Outputs from Cochrane database of systematic reviews
#5,560
of 11,660 outputs
Outputs of similar age
#29,635
of 174,708 outputs
Outputs of similar age from Cochrane database of systematic reviews
#49
of 111 outputs
Altmetric has tracked 17,360,236 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,660 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.0. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,708 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 111 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.